Cargando…

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

BACKGROUND: Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. This phase I trial was conducted to determine the safety profile, maximal tolerated dose, and recommended phase II...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chon, Hye Sook, Kang, Sokbom, Lee, Jae K., Apte, Sachin M., Shahzad, Mian M., Williams-Elson, Irene, Wenham, Robert M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465458/ https://www.ncbi.nlm.nih.gov/pubmed/28595616 http://dx.doi.org/10.1186/s12885-017-3394-2

Ejemplares similares

Ridaforolimus
Publicado: (2012)

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
por: Pearson, Andrew D.J., et al.
Publicado: (2016)

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
por: Seki, Yoshitaka, et al.
Publicado: (2011)

Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells
por: Morgan, Sherif S, et al.
Publicado: (2014)

A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
por: Liu, Lian, et al.
Publicado: (2013)

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
por: Bicaku, E, et al.
Publicado: (2012)

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth
por: MARCHION, DOUGLAS C., et al.
Publicado: (2013)

Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel
por: CHEN, NING, et al.
Publicado: (2014)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
por: Kaye, S, et al.
Publicado: (2012)

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
por: Alhalabi, Omar, et al.
Publicado: (2023)

Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours
por: Harries, M, et al.
Publicado: (2004)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
por: Molife, L Rhoda, et al.
Publicado: (2014)

Major vascular injury during gynecologic cancer surgery
por: Buras, Andrea L., et al.
Publicado: (2021)

Pharmacokinetic Evaluation of a DSPE-PEG(2000) Micellar Formulation of Ridaforolimus in Rat
por: Remsberg, Connie M., et al.
Publicado: (2012)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

Treating metastatic soft-tissue or bone sarcomas – potential role of ridaforolimus
por: Keedy, Vicki L
Publicado: (2012)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
por: Brana, I, et al.
Publicado: (2014)

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
por: Colombo, N, et al.
Publicado: (2013)

Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors
por: Wheler, Jennifer, et al.
Publicado: (2017)

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)
por: Leal, Ticiana A., et al.
Publicado: (2022)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
por: Elsayed, Ahmed Gamal, et al.
Publicado: (2017)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
por: Becker, Marc A., et al.
Publicado: (2016)

Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
por: Lee, Matilda Xinwei, et al.
Publicado: (2022)

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
por: Vonderheide, Robert H., et al.
Publicado: (2013)

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer
por: Lush, Richard M., et al.
Publicado: (2012)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial.
por: Zielinski, C. C., et al.
Publicado: (1998)

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel
por: Jilaveanu, Lucia B., et al.
Publicado: (2013)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
por: Lassen, U, et al.
Publicado: (2010)

Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2019)

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Survival outcomes in patients with oropharyngeal cancer treated with carboplatin/paclitaxel and concurrent radiotherapy
por: Roskies, M., et al.
Publicado: (2016)

CARBOPLATIN-PACLITAXEL INDUCED ACUTE MULTI-VESSEL CORONARY THROMBOSIS
por: Fanous, Hanna, et al.
Publicado: (2022)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3hj5si3b77hp9hj3etj1m7694v